Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder

被引:45
作者
Dunayevich, Eduardo
Ascher-Svanum, Haya
Zhao, Fangyi
Jacobson, Jennie G.
Phillips, Glenn A.
Dellva, Mary Anne
Green, Alan I.
机构
[1] Orexigen Therapeut, San Diego, CA 92130 USA
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] Dartmouth Coll Sch Med, Dept Psychiat, Lebanon, NH USA
关键词
D O I
10.4088/JCP.v68n0801
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: Time to all-cause treatment discontinuation is considered a composite proxy measure of treatment efficacy, safety, and tolerability. Longer time to discontinuation of antipsychotic medication for any cause has been shown to be associated with greater symptom improvements in the treatment of schizophrenia. This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes. Method: Using pooled data from 4 randomized, double-blind antipsychotic trials of 24- to 28-weeks' duration. this study examined the association between time to all-cause treatment discontinuation and functional outcomes. as assessed by a disease-specific, clinician-rated measure (Quality of Life Scale [QLS]) and a generic. patient-reported measure (Medical Outcomes Study Short Form 36 [SF-36]). Patients in these trials had a DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder. This post hoc analysis used Pearson partial correlations to assess relationships between time to treatment discontinuation and changes in functional scores, adjusting for baseline scores. Repeated measures analyses were also conducted to compare post-baseline functional outcome change over time between completers and noncompleters. Results: Longer time to all-cause treatment discontinuation was found to be significantly associated with greater improvements in all assessed functional domains (p < .05). Patients who completed their respective trials (46.8%, 761/1627) experienced significantly greater improvement in functional outcome measures (in 4 QLS domains and SF-36 mental health component summary score; all, p < .001) compared to patients who discontinued for any cause. In addition, greater symptom improvement was significantly associated with greater functional improvements in assessed domains. Conclusions: Findings from this post hoc analysis illustrate the importance of longer treatment duration with antipsychotics for improving functional outcomes in the treatment of patients with schizophrenia.
引用
收藏
页码:1163 / 1171
页数:9
相关论文
共 24 条
[1]   Delayed-onset hypothesis of antipsychotic action - A hypothesis tested and rejected [J].
Agid, O ;
Kapur, S ;
Arenovich, T ;
Zipursky, RB .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (12) :1228-1235
[2]   Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care [J].
Ascher-Svanum, H ;
Faries, DE ;
Zhu, BJ ;
Ernst, FR ;
Swartz, MS ;
Swanson, JW .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (03) :453-460
[3]   Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization [J].
Bow-Thomas, CC ;
Velligan, DI ;
Miller, AL ;
Olsen, J .
PSYCHIATRY RESEARCH, 1999, 86 (02) :131-142
[4]   Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia [J].
Breier, A ;
Berg, PH ;
Thakore, JH ;
Naber, D ;
Gattaz, WF ;
Cavazzoni, P ;
Walker, DJ ;
Roychowdhury, SM ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (10) :1879-1887
[5]   Early prediction of antipsychotic response in schizophrenia [J].
Correll, CU ;
Malhotra, AK ;
Kaushik, S ;
McMeniman, M ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (11) :2063-2065
[6]   A meta-analysis of the efficacy of second-generation antipsychotics [J].
Davis, JM ;
Chen, N ;
Glick, ID .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (06) :553-564
[7]   Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes [J].
Dunayevich, Eduardo ;
Sethuraman, Gopalan ;
Enerson, Mark ;
Taylor, Cindy C. ;
Lin, Daniel .
SCHIZOPHRENIA RESEARCH, 2006, 86 (1-3) :300-308
[8]   THE QUALITY OF LIFE SCALE - AN INSTRUMENT FOR RATING THE SCHIZOPHRENIC DEFICIT SYNDROME [J].
HEINRICHS, DW ;
HANLON, TE ;
CARPENTER, WT .
SCHIZOPHRENIA BULLETIN, 1984, 10 (03) :388-398
[9]   Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life [J].
Ho, BC ;
Psych, MRC ;
Nopoulos, P ;
Flaum, M ;
Arndt, S ;
Andreasen, NC .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (09) :1196-1201
[10]   A SHARPER BONFERRONI PROCEDURE FOR MULTIPLE TESTS OF SIGNIFICANCE [J].
HOCHBERG, Y .
BIOMETRIKA, 1988, 75 (04) :800-802